Françoise Weber

1.1k total citations
17 papers, 867 citations indexed

About

Françoise Weber is a scholar working on Epidemiology, Immunology and Hepatology. According to data from OpenAlex, Françoise Weber has authored 17 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 8 papers in Immunology and 5 papers in Hepatology. Recurrent topics in Françoise Weber's work include Influenza Virus Research Studies (12 papers), Immunotherapy and Immune Responses (7 papers) and Hepatitis Viruses Studies and Epidemiology (5 papers). Françoise Weber is often cited by papers focused on Influenza Virus Research Studies (12 papers), Immunotherapy and Immune Responses (7 papers) and Hepatitis Viruses Studies and Epidemiology (5 papers). Françoise Weber collaborates with scholars based in France, Mexico and Belgium. Françoise Weber's co-authors include Arvydas Ambrozaitis, Isabel Leroux‐Roels, Camille Salamand, Robert Booy, Pierre Van Damme, Giancarlo Icardi, David J. Holland, Jim Reid, Jeff Karrasch and Mélanie Saville and has published in prestigious journals such as The Journal of Infectious Diseases, Vaccine and BMC Medicine.

In The Last Decade

Françoise Weber

17 papers receiving 831 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Françoise Weber France	15	537	380	258	184	131	17	867
Mimi Guebre‐Xabier United States	15	279 0.5×	335 0.9×	41 0.2×	34 0.2×	182 1.4×	24	858
E. Stein Esser United States	13	133 0.2×	327 0.9×	441 1.7×	282 1.5×	96 0.7×	18	714
Tomoko Kiyohara Japan	17	448 0.8×	68 0.2×	47 0.2×	25 0.1×	124 0.9×	35	837
Eun Kim United States	6	90 0.2×	92 0.2×	145 0.6×	72 0.4×	81 0.6×	16	567
Sonia Resik Cuba	15	236 0.4×	69 0.2×	46 0.2×	20 0.1×	37 0.3×	43	636
Jesse Bodle Australia	7	180 0.3×	119 0.3×	111 0.4×	63 0.3×	46 0.4×	10	346
Suzanne Jones United Kingdom	9	224 0.4×	131 0.3×	46 0.2×	20 0.1×	86 0.7×	12	490
Youri Lee United States	19	475 0.9×	287 0.8×	23 0.1×	9 0.0×	135 1.0×	47	820
Mario Cortese United States	9	342 0.6×	525 1.4×	13 0.1×	7 0.0×	232 1.8×	11	827
Germie P. J. M. van den Dobbelsteen Netherlands	18	686 1.3×	180 0.5×	17 0.1×	7 0.0×	128 1.0×	39	999

Countries citing papers authored by Françoise Weber

Since Specialization

Citations

This map shows the geographic impact of Françoise Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Françoise Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Françoise Weber more than expected).

Fields of papers citing papers by Françoise Weber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Françoise Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Françoise Weber. The network helps show where Françoise Weber may publish in the future.

Co-authorship network of co-authors of Françoise Weber

This figure shows the co-authorship network connecting the top 25 collaborators of Françoise Weber. A scholar is included among the top collaborators of Françoise Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Françoise Weber. Françoise Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Han, Sang Hoon, Jun Hee Woo, Françoise Weber, et al.. (2013). Immunogenicity and safety of Intanza^®/IDflu^®intradermal influenza vaccine in South Korean adults: A multicenter, randomized trial. Human Vaccines & Immunotherapeutics. 9(9). 1971–1977. 14 indexed citations

Leroux‐Roels, Isabel & Françoise Weber. (2013). Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age. Human Vaccines & Immunotherapeutics. 9(1). 115–121. 28 indexed citations

Prymula, Roman, et al.. (2012). Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey. Advances in Therapy. 29(1). 41–52. 18 indexed citations

Booy, Robert, et al.. (2011). Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Advances in Therapy. 28(8). 640–649. 31 indexed citations

Coudeville, Laurent, Philippe André, Fabrice Bailleux, Françoise Weber, & Stanley A. Plotkin. (2010). A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Human Vaccines. 6(10). 841–848. 31 indexed citations

Ambrozaitis, Arvydas, et al.. (2010). Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial. Human Vaccines. 6(4). 346–354. 64 indexed citations

Viala-Danten, Muriel, et al.. (2010). Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Human Vaccines. 6(4). 336–345. 32 indexed citations

Morélon, Emmanuel, Claire Pouteil Noble, R. Cahen, et al.. (2010). Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine. 28(42). 6885–6890. 42 indexed citations

Icardi, Giancarlo, et al.. (2009). Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine. 27(52). 7304–7312. 143 indexed citations

10.

Beran, Jiřı́, Arvydas Ambrozaitis, Alvydas Pranas Laiškonis, et al.. (2009). Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Medicine. 7(1). 13–13. 82 indexed citations

11.

Holland, David J., Robert Booy, Ferdinandus de Looze, et al.. (2008). Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial. The Journal of Infectious Diseases. 198(5). 650–658. 207 indexed citations

12.

Leroux‐Roels, Isabel, Eva Vets, Michael Seiberling, et al.. (2008). Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine. 26(51). 6614–6619. 99 indexed citations

13.

López, Eduardo, María M Contrini, Betzana Zambrano, et al.. (2006). Hepatitis A vaccination of Argentinean infants: Comparison of two vaccination schedules. Vaccine. 25(1). 102–108. 14 indexed citations

14.

Overbosch, D., et al.. (2006). Combined Typhoid Fever and Hepatitis A Vaccine: Comparison of Immunogenicity and Safety to Concomitant Monovalent Vaccine over 3 Years. Journal of Travel Medicine. 12(6). 319–326. 27 indexed citations

15.

Dagan, Ron, David Greenberg, & Françoise Weber. (2005). Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine. 23(44). 5144–5148. 12 indexed citations

16.

Lolekha, Somsak, et al.. (2003). Immunogenicity and Safety of Two Doses of a Paediatric Hepatitis A Vaccine in Thai Children: Comparison of Three Vaccination Schedules. Journal of Tropical Pediatrics. 49(6). 333–339. 15 indexed citations

17.

Beran, Jiřı́, Roman Chlíbek, & Françoise Weber. (2003). A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine. 21(32). 4650–4654. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact